1 / 81

Chemoradiotherapy for Rectal cancer

Chemoradiotherapy for Rectal cancer. Dr. A . Sun Myint Lead Clinician GI Tumour Group Clatterbridge Centre for Oncology. Association of Coloproctology of Great Britain and Ireland M62 Coloproctology Course - March 23 rd 2007. Background.

cyma
Télécharger la présentation

Chemoradiotherapy for Rectal cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chemoradiotherapy for Rectal cancer Dr. A . Sun Myint Lead Clinician GI Tumour Group Clatterbridge Centre for Oncology Association of Coloproctology of Great Britain and Ireland M62 Coloproctology Course - March 23rd 2007

  2. Background • In the UK over 10,000 new rectal cancer • Five year survival 50% (NBOCAP-2006) • Nearly half will develop recurrences • At presentation 30% T3/T4 N + MO • Preoperative radiotherapy reduce LR • So far, no survival advantage

  3. Treatment Options Options Improvements • Surgery TME / Training Sub specialisation • Radiotherapy Pre operative Chemoradiotherapy Post operative • Chemotherapy Advance /metastatic Adjuvant New agents

  4. Radiotherapy

  5. Preoperative Radiotherapy Short course or Long course? • Short course • Long course

  6. Preoperative Radiotherapy Short course or Long course? • Short course - Mobile operable tumour • Long course - Fixed / Tethered tumour 30%( MRI defined CRM +)

  7. Preoperative Radiotherapy Short course or Long course? • Short course - Mobile operable tumour • Long course - Fixed / Tethered tumour ( MRI defined CRM +)

  8. Improving Outcomes • Add chemotherapy to radiation • Increase radiation dose

  9. Chemo-radiotherapy Concurrent Chemotherapy + RT • 5FU • 5FU / FA • 5FU infusion + Irino / Oxaliplatin • Capecitabine + Irino / Oxaliplatin+ EGFR • Capecitabine + Irino / Oxaliplatin+ VEGFR

  10. Oxaliplatin is a radiosensitiser in HT-29 xenograft models Tumour volume 160 120 80 40 0 Control Oxaliplatin 5mg/kg Radiation only (5Gy) Oxaliplatin + radiation 01 05 09 13 17 21 Days post-treatment Blackstock A et al. Int J Rad Oncol Biol Phys 2000;16:92–94

  11. Comparative tumor sterilization rate by treatment modality

  12. Is chemo-Radiotherapy better than RT alone?

  13. EORTC Rectal cancer trial T3/T4 rectal cancer n=1011

  14. EORTC Rectal cancer trial Bossett al ASCO 2005

  15. EORTC Rectal cancer trial Bossett al ASCO 2005

  16. FFCD 9203- Rectal cancer trial T3/T4 rectal cancer n=733 JP Gerard et al ASCO 2005

  17. FFCD 9203- Rectal cancer trial JP Gerard et al ASCO 2005

  18. FFCD 9203- Rectal cancer trial JP Gerard et al ASCO 2005

  19. Chemo RT vs. Radiotherapy Local control in T3/T4 rectal cancer

  20. Pre-operative Radiotherapy better than post op RT?

  21. German pre op. vs. post operative chemoradiotherapy for rectal cancer Sauer et al N Engl J Med (2004) 351;17 1731-01740

  22. German pre op. vs. post operative chemoradiotherapy for rectal cancer Sauer et al N Engl J Med (2004) 351;17 1731-01740

  23. German pre op. vs. post operative chemoradiotherapy for rectal cancer Sauer et al N Engl J Med (2004) 351;17 1731-01740

  24. Newer agents for chemoradiotherapy

  25. Chemoradiotherapy • 5FU bolus • 5FU+ FA • Infusional 5FU • Capecitabine • Irinotecan +Cape NWCCOG 1+ RICE • Oxaliplatin +CapeCORE/ SOCRATES • Triplet therapyIr/Oxali + MdG+ VEGF R A D I O T H E R A P Y

  26. Pre-operative 5-FU chemoradiation: • 5-FU-based chemoradiation has become part of standard pre-operative therapy for rectal cancer • effective downstaging • 10–30% pCR rates • Protracted infusion of 5-FU with postoperative radiotherapy improves survival versus bolus5-FU1 1O’Connell MJ et al. N Engl J Med 1994;331:502–7

  27. Infused versus bolus 5-FU during pelvic radiation Overall survival (%) Infused 5-FU (n=328) Bolus 5-FU (n=332) 100 80 60 40 20 0 Log rank p=0.005 Cox model p=0.01 0 1 2 3 4 Years after randomisation O’Connell MJ et al. N Engl J Med 1994;331:502–7

  28. Capecitabine + radiation

  29. capecitabine plus radiotherapy • Infused 5-FU is cumbersome and inconvenient for patients • Oral capecitabine simplifies chemoradiation and is highly appealing to patients • Potential for enhanced therapeutic ratio • capecitabine generates 5-FU preferentially in tumour via thymidine phosphorylase (TP)1 • radiotherapy further upregulates TP in tumour2 1Miwa M et al. Eur J Cancer 1998;34:1274–81 2Sawada N et al. Clin Cancer Res 1999;5:2948–53

  30. Irradiation upregulates TP TP (units/mg protein) 5Gy 2.5Gy Control 25 20 15 10 5 0 * * * * * * * * * 0 3 6 9 12 15 18 21 Days after X-ray irradiation Sawada N et al. Clin Cancer Res 1999;5:2948–53 *p<0.05

  31. capecitabine enhances activity of radiation in WiDr xenografts, Tumour inhibition (%) 120 100 80 60 40 20 0 * 5Gy 5-FU Xeloda Xeloda + 5Gy 5-FU + 5Gy Sawada N et al. Clin Cancer Res 1999;5:2948–53 *p<0.05

  32. Capecitabine chemoradiation: • Oral capecitabine is replacing 5-FU in chemoradiation • capecitabine is highly effective and well tolerated in combination with radiotherapy • capecitabine simplifies chemoradiation and is highly appealing to patients and clinicians alike

  33. Chemoradiation in rectal cancer: German phase II study (n=68) • Male / female (%) 63 / 37 • Median age 65 years • ECOG 0/1 (%) 54 / 41 • T3 / T4 (%)48 / 52 (57% N1–3) Day 1 8 15 22 29 35 50.4Gy radiotherapy 1.8Gy/fraction 825mg/m2twice daily Continuous (days 1–37) Dunst J et al. Proc Am Soc Clin Oncol 2003;22:277 (Abst 1113)

  34. capecitabine chemoradiation:efficacy 1Dunst J et al. Eur J Cancer 2003;1(Suppl. 5):S86 (Abst 282) 2Lin E et al. Proc Am Soc Clin Oncol 2003;22:287 (Abst 1152)

  35. No grade 4 adverse events Grade 1/2 Grade 3 capecitabine chemoradiation: Toxicity Patients (%) 80 60 40 20 0 Diarrhoea Local Pain Hand-foot Nausea erythema syndrome Dunst J et al. Eur J Cancer 2003;1(Suppl. 5):S86 (Abst 282)

  36. NSABP R-04 rectal cancer trial Objectives • DFS • recurrence rate • pCR • safety capecitabine continuously throughout radiotherapy (50.4Gy*) S U R G E R Y Resectable rectal cancer, stage II–III n=1600 5-FU continuous infusion throughout radiotherapy (50.4Gy*) *Plus 5.4Gy for fixed tumours

  37. Chemoradiation using Oxaliplatin combination

  38. capecitabine/oxaliplatin chemoradiation 1Glynne-Jones R et al. Proc Am Soc Clin Oncol 2003;22:292 (Abst 1174)2Rödel C et al. J Clin Oncol 2003;21:3098–104

  39. CORE: European study Day 1 8 15 2229 Radiotherapy 45Gy/25 fractions capecitabine825mg/m2 twice daily Monday to Friday Oxaliplatin50mg/m2weekly • CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision

  40. Chemoradiotherapy using Irinotecan combination

  41. RICE - NWCCOG study Day 1 8 15 2229 Radiotherapy 45Gy/25 fractions capecitabine825mg/m2 twice daily Monday to Friday IRINOTECAN 60mg/m2 weekly S. Gollins, S.Myint, E. Levine et alProc Am Soc Clin Oncol 2006;24:617s (Abst 13519)

  42. Chemoradiotherapy • 5FU bolus • 5FU+ FA • Infusional 5FU • Capecitabine • Irinotecan +Cape NWCCOG 1+ RICE • Oxaliplatin +CapeCORE/ SOCRATES • Triplet therapyIr/ Oxali + cape+ EGF R A D I O T H E R A P Y ARISTOTLE

  43. Reducing Toxicity from CRT

  44. Toxicity • Chemoradiotherapy is more toxic than radiotherapy alone • To reduce toxicity:- Preoperative rather than post op Radiation volume Dose, fractionation and time Radiation techniques

More Related